Products

Fmoc-N-Me-Ile-OH (N‑α‑Fmoc‑N‑α‑methyl‑L‑isoleucine) is a non‑natural, N‑methylated amino acid derivative specifically designed for Fmoc‑based solid‑phase peptide synthesis (SPPS). Structurally, the molecule consists of an isoleucine backbone where the α‑amino group bears an N‑methyl substituent, and the secondary amine is protected by the base‑labile 9‑fluorenylmethyloxycarbonyl (Fmoc) group. The C‑terminal carboxylic acid remains free for coupling. The presence of the N‑methyl group introduces conformational constraint into the peptide backbone, as N‑methylated amides adopt distinct cis/trans preferences compared to unsubstituted amides. This constrained architecture enhances the metabolic stability of peptides by rendering the amide bond resistant to proteolytic cleavage, while also improving membrane permeability and oral bioavailability in both in vitro and in vivo pharmacological studies. The Fmoc group, which is cleaved under mild basic conditions (20% piperidine in DMF), is orthogonal to acid‑labile side‑chain protecting groups, ensuring compatibility with standard Fmoc SPPS protocols. Fmoc-N-Me-Ile-OH is a building block for the introduction of N‑α‑methyl‑isoleucine amino acid residues into synthetic peptides using Fmoc SPPS.

Fmoc-Thr(Trt)-OH (Fmoc-O-trityl-L-threonine) is a strategically protected derivative of the naturally occurring amino acid L-threonine, specifically designed for Fmoc-based solid‑phase peptide synthesis (SPPS). Structurally, the molecule consists of a threonine backbone where the α‑amino group is protected by the base‑labile 9‑fluorenylmethyloxycarbonyl (Fmoc) group, while the side‑chain hydroxyl group is masked by the bulky, acid‑labile trityl (Trt, triphenylmethyl) protecting group. The C‑terminal carboxylic acid remains free for coupling to the resin or to the preceding amino acid residue in the growing peptide chain. This dual protection strategy — orthogonal base‑labile Fmoc and acid‑labile Trt — provides precise control over deprotection sequences in SPPS.

Fmoc-Glu-OtBu (N‑Fmoc‑L‑glutamic acid 1‑tert‑butyl ester) is a selectively protected derivative of the naturally occurring amino acid L‑glutamic acid, specifically designed for Fmoc‑based solid‑phase peptide synthesis (SPPS) and the preparation of γ‑glutamyl peptides. Structurally, the molecule consists of a glutamic acid backbone where the α‑amino group is protected by the base‑labile 9‑fluorenylmethyloxycarbonyl (Fmoc) group, while the side‑chain γ‑carboxyl group is protected as a tert‑butyl ester (OtBu). The α‑carboxyl group remains free for coupling to the resin or to the preceding amino acid residue in the growing peptide chain. This orthogonal protection strategy — base‑labile Fmoc for the α‑amino group and acid‑labile tBu ester for the side‑chain — enables precise control over deprotection sequences in SPPS. The tBu ester is cleaved under strongly acidic conditions (typically 50% TFA in DCM), while the Fmoc group is removed with piperidine in DMF, allowing the side‑chain carboxyl to be selectively unmasked after the completion of chain assembly. This selective unmasking capability makes Fmoc-Glu-OtBu an indispensable building block for the synthesis of branched esters, amides, lactams, and lactones containing the glutamyl unit

Fmoc-Thr(tBu)-OH (N-α-Fmoc-O-tert-butyl-L-threonine, CAS 71989-35-0) is a protected derivative of the naturally occurring amino acid L-threonine, featuring a 9-fluorenylmethoxycarbonyl (Fmoc) group protecting the N-terminal α-amino function and a tert-butyl ether protecting the β-hydroxyl side chain. The threonine backbone contains two chiral centers at the α-carbon and the β-carbon, with the natural L-threonine configuration (2S,3R). The tert-butyl group (tBu) on the hydroxyl side chain is stable under the basic conditions required for Fmoc removal but is readily cleaved by trifluoroacetic acid (TFA) during final peptide deprotection, making Fmoc-Thr(tBu)-OH a standard building block in Fmoc-based solid-phase peptide synthesis (SPPS). Unlike most amino acids where side-chain protection is optional, threonine requires careful handling of its reactive secondary hydroxyl group — free threonine hydroxyls can participate in undesired side reactions during chain assembly, including acylation leading to branched peptides and dehydration to form dehydrobutyrine. The tBu group effectively addresses these risks by rendering the hydroxyl inert under standard SPPS conditions while remaining orthogonal to the Fmoc removal strategy. This orthogonal protection logic enables the reliable incorporation of threonine residues into peptide chains of any length and complexity, from simple therapeutic peptides to complex depsipeptides containing ester linkages.

Fmoc-Ser(tBu)-OH (N-α-fluorenylmethyloxycarbonyl-O-tert-butyl-L-serine) is a standard Fmoc-protected amino acid building block featuring a tert-butyl ether protecting group on the serine hydroxyl side chain. The Fmoc group, which protects the α-amino function, is selectively removed under mild basic conditions (20% piperidine in DMF), while the acid-labile tert-butyl (tBu) group remains intact throughout the chain assembly process, only being cleaved during the final TFA-mediated global deprotection step. This orthogonal protecting group strategy—base-labile Fmoc for the α-amine and acid-labile tBu for the side chain—is the cornerstone of standard Fmoc/tBu solid-phase peptide synthesis (Fmoc SPPS) and is employed in virtually all automated peptide synthesizers worldwide.

Fmoc-Phe-OH (N-α-Fmoc-L-phenylalanine) is a cornerstone building block in Fmoc-based solid-phase peptide synthesis (SPPS), combining the base‑labile Fmoc protecting group with the native L‑phenylalanine amino acid. The Fmoc (9‑fluorenylmethyloxycarbonyl) group is particularly valued in peptide synthesis because it can be removed under mild alkaline conditions (typically 20% piperidine in DMF) without affecting the integrity of the peptide backbone or the acid‑sensitive side‑chain protecting groups. The aromatic benzyl side chain of Fmoc-Phe-OH imparts predictable hydrophobicity and specific structural properties to synthesized peptides, making it essential for introducing phenylalanine residues in therapeutic peptides, structure‑activity relationship (SAR) studies, and peptidomimetic development. The rigid planar structure of the Fmoc group also enables self‑assembling properties, with Fmoc‑Phe conjugates being widely studied for the formation of functional hydrogels and biomaterials in tissue engineering and regenerative medicine.